No added value of monitoring platelet function after ACS

Media formats available:

Preventive PCI versus only optimal medical therapy for vulnerable plaques
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC.24
Preventive PCI versus only optimal medical therapy for vulnerable plaques
- Marc Bonaca, MD
Self-assessment on statin eligibility without prescription using a web app
Self-assessment on statin eligibility without prescription using a web app
ACC.24
Self-assessment on statin eligibility without prescription using a web app
- Steven Nissen, MD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC.24
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- Michael Koren, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD

PACE-CME